Activated in tumors

Articles

• CCND1
  13 April 2004

  cyclin-D1, CYLD1, BCL1
  The proto-oncogene cyclin D1 has been implicated in the genesis of a large proportion of human tumors from diverse histological origins.
  Function
  activator of cdk4 and cdk6 in progression through the G1 phase of the cell cycle
  Pathology
  cyclin D1 overexpression in mantle cell lymphoma
  The cytogenetic and diagnostic hallmark of mantle cell lymphoma (MCL) is translocation t(11;14)(q13;q32), resulting in overexpression of cyclin D1.
  There are rare cyclin (...)

• KIT
  12 December 2003

  c-kit; CD117
  Definition: The proto-oncogene c-kit / CC117 is a receptor tyrosine kinase recognized to initiate essential signal transduction pathways that transmit biological signals for cellular proliferation, differentiation, and metastasis. Aberrant expression or mutation of c-kit has been shown to be involved in the pathogenesis of many cancers. See also CD117 IHCDB
  Expression in cells
  c-KIT positive spermatogonia
  Expression in tumors (Exemples)
  chromophobe renal cell (...)

• PDGFRA
  12 December 2003

  platelet-derived growth factor receptor (PDGFR) alpha, PDGFR-alpha

• ERBB2
  11 February 2006

  ERBB2 ; CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1; c-erbb2
  The oncogene originally called HER/NEU was derived from rat neuro/glioblastoma cell lines. It encodes a tumor antigen, p185, which is serologically related to EGFR, the epidermal growth factor receptor (MIM.131550).
  ERBB2 encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases (ERBBs).
  ERBB2 has no ligand binding domain of its own and therefore cannot bind growth factors. (...)

• HRAS
  14 April 2004

  Pathology
  Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties.
  somatic mutations in:
  colorectal adenocarcinoma
  bladder carcinoma
  thyroid follicular carcinoma
  Spit nevus / Spitzoid tumors
  malignant ectomesenchymoma (#26872011#)
  Germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated (...)

• KRAS
  14 April 2004

  Ki-ras, KRAS2